Evolving Treatment Standards in Non-Clear Cell RCC

Author(s):

Martin H. Voss, MD, and Moshe Ornstein, MD, engage in a professional discourse concerning the current treatment standards and the evolving therapeutic landscape for non-clear cell renal cell carcinoma (RCC).

Now Viewing

EP: 1.Evolving Treatment Standards in Non-Clear Cell RCC

EP: 2.Extended Follow Up of KEYNOTE-B61

EP: 3.Ongoing Clinical Trials in the front-line setting of advanced non-clear cell RCC

EP: 4.STELLAR 304: Zanzalintinib plus nivolumab in non-clear cell RCC

EP: 5.Case Presentation: 61-year-old male Renal Cell Carcinoma

EP: 6.Use of Combination Regimens in Frontline RCC

EP: 7.Treatment Decision Making in first-line combinations for advanced RCC

EP: 8.AE Management for Combination Regimens in Advanced RCC

EP: 9.AE Management for Combination Regimens in Advanced RCC

EP: 10.Optimizing Treatment in Advanced RCC

EP: 11.Dr Albiges Discusses a Non-Clear Cell RCC Patient Profile

EP: 12.Updates in the Treatment Approach for Non-clear cell RCC

EP: 13.Dr Albiges Reviews Long term follow up data from KEYNOTE-B61

EP: 14.Emerging Therapies in the Front-line Setting of Advanced non-clear cell RCC

EP: 15.Biomarker-driven combination treatment approach in non-clear cell RCC (Met-driven)

EP: 16.Summary and Forward Looking for RCC

How has the treatment landscape evolved for patients with advanced nccRCC?

What are the available treatment options for patients with advanced nnRCC?
How are you choosing between the available options?